Vitisin B, a resveratrol tetramer from Vitis thunbergii var. taiwaniana, ameliorates impaired glucose regulations in nicotinamide/streptozotocin-induced type 2 diabetic mice

IF 3.3 3区医学 Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE

Journal of Traditional and Complementary Medicine Pub Date : 2023-09-01 DOI:10.1016/j.jtcme.2023.05.003

Yuh-Hwa Liu , Yin-Shiou Lin , Yi-Yan Sie , Ching-Chiung Wang , Chi-I Chang , Wen-Chi Hou

{"title":"Vitisin B, a resveratrol tetramer from Vitis thunbergii var. taiwaniana, ameliorates impaired glucose regulations in nicotinamide/streptozotocin-induced type 2 diabetic mice","authors":"Yuh-Hwa Liu , Yin-Shiou Lin , Yi-Yan Sie , Ching-Chiung Wang , Chi-I Chang , Wen-Chi Hou","doi":"10.1016/j.jtcme.2023.05.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and aim</h3><p>In Taiwan, <em>Vitis thunbergii</em> var. <em>taiwaniana</em> (VTT) is used in traditional medicine and as a local tea. VTT rich in resveratrol and resveratrol oligomers have been reported to exhibit anti-obesity and anti-hypertensive activities in animal models; however, no studies have investigated type 2 diabetes mellitus (T2DM) treatments. This study aimed to investigate the anti-T2DM effects of resveratrol tetramers isolated from the VTT in nicotinamide/streptozotocin (STZ)-induced Institute of Cancer Research (ICR) mice.</p></div><div><h3>Experimental procedure</h3><p>The oral glucose tolerance test (OGTT) was used to imitate postprandial blood glucose (BG) regulations in mice by pre-treatment with VTT extracts, resveratrol tetramers of vitisin A, vitisin B, and hopeaphenol 30 min before glucose loads. Vitisin B (50 mg/kg) was administered to treat T2DM-ICR mice once daily for 28 days to investigate its hypoglycemic activity.</p></div><div><h3>Results and conclusion</h3><p>Mice pre-treated with VTT-S-95EE, or vitisin B (100 mg/kg) 30-min before glucose loading showed significant reductions (<em>P</em> < 0.001) in the area under the curve at 120-min (BG-AUC<sub>0-120</sub>) than those without pre-treatment with VTT-S-95 E E or vitisin B. Vitisin B-treated T2DM mice showed hypoglycemic activities via a reduction in plasma dipeptidyl peptidase (DPP)-IV activities to maintain insulin actions and differed significantly than those of untreated T2DM mice (<em>P</em> < 0.05), and also reduced BG-AUC<sub>0-120</sub> and insulin-AUC<sub>0-120</sub> in the OGTT.</p><p>These <em>in vivo</em> results showed that VTT containing vitisin B would be beneficial for developing nutraceuticals and/or functional foods for glycemic control in patients with T2DM, which should be investigated further.</p></div>","PeriodicalId":17449,"journal":{"name":"Journal of Traditional and Complementary Medicine","volume":"13 5","pages":"Pages 479-488"},"PeriodicalIF":3.3000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Traditional and Complementary Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2225411023000585","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Background and aim

In Taiwan, Vitis thunbergii var. taiwaniana (VTT) is used in traditional medicine and as a local tea. VTT rich in resveratrol and resveratrol oligomers have been reported to exhibit anti-obesity and anti-hypertensive activities in animal models; however, no studies have investigated type 2 diabetes mellitus (T2DM) treatments. This study aimed to investigate the anti-T2DM effects of resveratrol tetramers isolated from the VTT in nicotinamide/streptozotocin (STZ)-induced Institute of Cancer Research (ICR) mice.

Experimental procedure

The oral glucose tolerance test (OGTT) was used to imitate postprandial blood glucose (BG) regulations in mice by pre-treatment with VTT extracts, resveratrol tetramers of vitisin A, vitisin B, and hopeaphenol 30 min before glucose loads. Vitisin B (50 mg/kg) was administered to treat T2DM-ICR mice once daily for 28 days to investigate its hypoglycemic activity.

Results and conclusion

Mice pre-treated with VTT-S-95EE, or vitisin B (100 mg/kg) 30-min before glucose loading showed significant reductions (P < 0.001) in the area under the curve at 120-min (BG-AUC_0-120) than those without pre-treatment with VTT-S-95 E E or vitisin B. Vitisin B-treated T2DM mice showed hypoglycemic activities via a reduction in plasma dipeptidyl peptidase (DPP)-IV activities to maintain insulin actions and differed significantly than those of untreated T2DM mice (P < 0.05), and also reduced BG-AUC_0-120 and insulin-AUC_0-120 in the OGTT.

These in vivo results showed that VTT containing vitisin B would be beneficial for developing nutraceuticals and/or functional foods for glycemic control in patients with T2DM, which should be investigated further.

Abstract Image

查看原文本刊更多论文

葡萄素B是一种来自台湾葡萄的白藜芦醇四聚体，改善了烟酰胺/链脲霉素诱导的2型糖尿病小鼠的葡萄糖调节

背景与目的在台湾，台湾黄（VTT）是一种传统医药和地方茶。据报道，富含白藜芦醇和白藜芦醇低聚物的VTT在动物模型中表现出抗肥胖和抗高血压活性；然而，没有研究对2型糖尿病（T2DM）的治疗进行调查。本研究旨在研究从VTT分离的白藜芦醇四聚体在烟酰胺/链脲佐菌素（STZ）诱导的癌症研究所（ICR）小鼠中的抗T2DM作用。实验方法采用口服葡萄糖耐量试验（OGTT）模拟小鼠餐后血糖（BG）的调节，方法是在葡萄糖负荷前30分钟用VTT提取物、葡萄素A、葡萄素B和霍普酚的白藜芦醇四聚体预处理。给予维生素B（50mg/kg）治疗T2DM-ICR小鼠，每天一次，持续28天，以研究其降血糖活性。结果和结论在葡萄糖负荷前30分钟用VTT-S-95EE或葡萄毒素B（100 mg/kg）预处理的小鼠在120分钟（BG-AUC0-120）时的曲线下面积比未用VTT-S95E或葡萄毒素B。Vitisin B处理的T2DM小鼠通过降低血浆二肽基肽酶（DPP）-IV活性来维持胰岛素作用而显示出降血糖活性，并且与未处理的T2糖尿病小鼠相比显著不同（P<；0.05），并且还降低了OGTT中的BG-AUC0-120和胰岛素-AUC0-1020。这些体内结果表明，含有葡萄素B的VTT有利于开发用于T2DM患者血糖控制的营养品和/或功能性食品，这一点有待进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Traditional and Complementary Medicine Medicine-Complementary and Alternative Medicine

CiteScore

9.30

自引率

6.70%

发文量

审稿时长

66 days

期刊介绍： eJTCM is committed to publish research providing the biological and clinical grounds for using Traditional and Complementary Medical treatments as well as studies that demonstrate the pathophysiological and molecular/biochemical bases supporting the effectiveness of such treatments. Review articles are by invitation only. eJTCM is receiving an increasing amount of submission, and we need to adopt more stringent criteria to select the articles that can be considered for peer review. Note that eJTCM is striving to increase the quality and medical relevance of the publications.